Doctors use ejection fraction percentages to categorize left-sided heart failure. According to a 2022 article, people with HFpEF have an ejection fraction of more than 50%.

For those patients with symptomatic heart failure with an ejection fraction less than 57%, there was clear evidence of the benefit from the ARNI compound. Now, this was not a prospectively powered ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Among patients with chronic kidney disease, heart failure with preserved ejection fraction was highly prevalent, according to data published in Kidney Medicine.Further, the presence of heart ...

Solomon, S. D., et al. (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. doi.org/10.1056/NEJMoa2407107.

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. Published online August 27, 2021. doi: 10.1056/NEJMoa2107038 ...

Heart Failure with Preserved Ejection Fraction (HFpEF): Dr Rajiv Kovil said, “HFpEF stands as a unique subtype of heart failure, characterized by heart failure symptoms despite a normal or ...

Heart failure with preserved ejection fraction occurs when the left ventricle of the heart is unable to relax and properly fill with blood, resulting in less blood being available to be pumped out ...

The analysis included 12,251 heart failure patients with mildly reduced and preserved ejection fraction who were followed up for a median of 2.2 to 2.3 years. The average age of participants was ...

1 Anker S. EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without ...

Empagliflozin receives Breakthrough Therapy designation in US for heart failure with preserved ejection fraction (). News release. Eli Lilly and Company. Accessed September 9, 2021. .

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease. November 24th 2020EP. 2: The Progressive ...